Cephalon, Inc.
http://www.cephalon.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cephalon, Inc.
China’s IPO Tightening Adds To Uncertainties Over Biotechs Going Public
China’s top securities regulator is slowing down the review of initial public offering applications across the board to “stabilize” the stock market. But event prior to the move, Chinese biotechs were operating already under a continuously tightening IPO environment.
Sandoz Looks To Join EU Trastuzumab Party With CHMP Thumbs Up
Sandoz looks to be in line for an EU-wide approval for its trastuzumab biosimilar during 2023, with the backing of the EMA’s Committee for Medicinal Products for Human Use.
Finance Watch: Two Biopharma IPOs Bring US Total To 17
Public Company Edition: Neumora grossed $250m and RayzeBio raised $311m in the first initial public offerings since early August. Also, ImmunityBio completes $470m in equity and debt financings, Bausch + Lomb sells $1.4bn worth of notes and Arbutus is among firms making cuts to conserve cash.
AMO Pharma Shows Weakness In Myotonic Dystrophy
A pivotal miss leaves the company more reliant on earlier-stage pipeline programs as it talks to regulators about the path forward for its lead product.
Company Information
- Other Names / Subsidiaries
-
- Arana Therapeutics (Peptech and EvoGenix)
- BioAssets Development Corporation
- Ception Therapeutics
- ChemGenex Pharmaceuticals Limited
- CIMA Labs
- Gemin X Pharmaceuticals
- Zeneus Pharma
- Mepha
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice